Ads
related to: drugs approved for prostate cancer- HCP Access & Support
Explore HCP Support Information and
Coverage Tools For Patients.
- Treatment Guidelines
Review NCCN and AUA Guidelines That
Support the Use of XTANDI®.
- HCP Resources
Useful Resources about XTANDI® for
Your Office and Your Patients
- Important Safety Info
Safety Profile & Adverse Reactions
For XTANDI® (enzalutamide).
- HCP Access & Support
Search results
Results from the WOW.Com Content Network
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
In doing so, it prevents the effects of these hormones in prostate cancer. [10] Abiraterone acetate was described in 1995, and approved for medical use in the United States and the European Union in 2011. [11] [2] It is on the World Health Organization's List of Essential Medicines. [12] It is available as a generic medication. [13]
Apalutamide was approved by the Food and Drug Administration in the United States, under the brand name Erleada, for the treatment of non-metastatic castration-resistant prostate cancer in February 2018. [8] [9] It was subsequently approved in Canada, the European Union, and Australia. [42] [6]
[13] [102] In men with early prostate cancer, bicalutamide monotherapy has been found to increase non-prostate cancer mortality. [26] [124] [13] The reasons for the increase in mortality with bicalutamide in these men are unknown, but possible factors could include androgen deprivation or drug-related toxicity of bicalutamide. [125] [126]
Viadur was approved by the FDA for palliative treatment of advanced prostate cancer on 6 March 2000. [7] Eligard was approved by the FDA for palliative treatment of advanced prostate cancer on 24 January 2002. [5] Fensolvi was approved by the FDA for children with central precocious puberty on 4 May 2020. [6] [46]
Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC. [ 11 ] [ 12 ] [ 2 ] [ 13 ] [ 1 ] Shortly afterward, sipuleucel-T was added to the compendium of cancer treatments published by the National Comprehensive Cancer Network (NCCN) as a "category ...
Ads
related to: drugs approved for prostate cancer